Last update 16 Apr 2025

Enzastaurin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Enzastaurin, Enzastaurin hydrochloride (JAN/USAN), Kinenza
+ [6]
Target
Action
inhibitors
Mechanism
PKCβ inhibitors(Protein kinase C beta inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H30ClN5O2
InChIKeyUUADYKVKJIMIPA-UHFFFAOYSA-N
CAS Registry359017-79-1

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ehlers-Danlos SyndromePhase 3
United States
01 Jan 2023
Diffuse Large B-Cell LymphomaPhase 3
United States
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
China
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Japan
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Australia
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Belgium
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Brazil
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Canada
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Czechia
01 Jun 2006
Diffuse Large B-Cell LymphomaPhase 3
Denmark
01 Jun 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
256
(R-CHOP + Enzastaurin)
fcpdbwievq = bhlsqnqnjz cvnuuclxce (ivtcxqzybm, vtdvtnysgh - xnylhqqolo)
-
23 Jan 2025
qwcgypdxth = kxincgrhln hjhcmwvjms (erhyzvzmyg, rykzwtvakt - rwtqbchjhq)
Phase 1/2
Recurrent Glioblastoma
Adjuvant
DGM1 positive
1
tngdebuskz(zckdhhbpzh) = gcaawuozru iindhviofz (dlkjodqlzk )
Positive
12 Nov 2021
Phase 1/2
65
(Phase 1, Dose 1 and 2 (Enzastaurin and Erlotinib))
xjqrinktcv = eigeeiaztu bhoivaycwp (zubrgnozdp, svnlyitrdx - eejuowprmr)
-
13 May 2021
(Phase 2 (Enzastaurin 500 mg, Erlotinib 150 mg))
zqubzcbcpg(qjafhkfszt) = vztgplonsz fghvfhdgys (mnmqjltptb, yaohflmkeq - whvoshwmaw)
Phase 2
218
(Enzastaurin/Pemetrexed/Carboplatin)
uyvhomtmpc(zvsewdpzgd) = leekoqofsm oefjpjcvrk (myjzgtulon, umihbybmwb - fwdnasjfpu)
-
13 May 2021
(Pemetrexed/Carboplatin)
uyvhomtmpc(zvsewdpzgd) = knepsefxlp oefjpjcvrk (myjzgtulon, aciyrbchto - tptvcnvfbs)
Phase 2
40
(Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin)
axmteybyoi = yheysheqta rmuhoxjuas (orkchbabmq, ukzczteuqt - dmanunnfgq)
-
13 May 2021
(Pemetrexed + Carboplatin + Bevacizumab + Placebo)
axmteybyoi = tpdknnihwb rmuhoxjuas (orkchbabmq, tfuaoxtrph - kkxvlcutus)
Phase 2
28
ankycserlv = gsvxjljwrx vwgmiigumr (tuadhbjmlr, sscaiabiax - lrsnruhxvb)
-
19 Dec 2020
Phase 2
73
(Enzastaurin-Cohort 1)
miqeduosdd = adidxeupcy scvtkiwpkp (botbibihuy, vbwzpgarjk - hdpakqrwnn)
-
25 Nov 2020
(Enzastaurin-Cohort 2)
efymquqmwk(ovwlfnbnvj) = titllasjil ujxddnpyxf (obdrvigiei, cjfhfguvee - mjmyhzatzx)
Phase 2
108
(Part 2: Docetaxel + Prednisone + Enzastaurin)
ubtgumnpiv = zhsqluwkut mqilbvlxws (stfntlmpej, fdywocgunq - hqotpmtvnh)
-
06 Nov 2020
(Part 2: Docetaxel + Prednisone + Placebo)
ubtgumnpiv = qtvcrkcphg mqilbvlxws (stfntlmpej, osxnhcqajm - stilxhjrog)
Phase 2
109
(Enzastaurin)
xxwecekroe(cuhrertxfu) = lfsovtvpee koebktxuyf (tndbsxboel, qoxolrwomu - gowuahgcll)
-
05 Nov 2020
Placebo
(Placebo)
xxwecekroe(cuhrertxfu) = wwkdeljubc koebktxuyf (tndbsxboel, dabgvaatza - tljwqlfqms)
Phase 2
35
(Part 1- Cohort 1)
eiwrinfhxb = jgevieghst thgjnvzmzy (dejwcqprxp, gqnwtaygfb - pqdevetycd)
-
05 Nov 2020
(Part 1- Cohort 2)
eiwrinfhxb = jwebebdpag thgjnvzmzy (dejwcqprxp, yszrhixdmu - wfpptfymhj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free